PRESS-RELEASE ·Filed Mar 25, 2026
Press release: earnings
Actionable Insight • Neutral
Traders should await the actual earnings release and call on April 29 for material updates. No action warranted based on this notice alone.
Final — all horizons settled through T+60d
REGN ▼ -18.73% at T+60d
NEUTRAL call ✗ call lost -18.73% · α vs SPY -34.13% · entry $753.70 → $612.50
T+1d
-2.10%
call -2.10% · α -0.42%
$737.85
settled 6mo ago
T+5d
+1.09%
call +1.09% · α -0.54%
$761.95
settled 6mo ago
T+20d
-0.31%
call -0.31% · α -10.98%
$751.35
settled 5mo ago
T+60d
-18.73%
call -18.73% · α -34.13%
$612.50
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Regeneron Pharmaceuticals announced it will release its first quarter 2026 financial results on April 29, 2026, followed by a conference call. The press release contains no financial data, guidance, or material operational updates — it is purely a scheduling notice.
Key Facts
- Regeneron will report Q1 2026 earnings on April 29, 2026, before market open.
- Conference call scheduled for 8:30 AM ET on the same day.
- No financial results, guidance, or operational updates were disclosed in this release.
- This is a routine earnings announcement notice, not a results release.
Financial Impact
None disclosed — no financial data released
Risk Factors
- Earnings could miss consensus expectations given recent insider selling, though minimal in size.
- Potential for volatility post-earnings if guidance is lowered or results disappoint.
Market Snapshot
Exchange
Nasdaq
Analyst Consensus
75% bullish (36 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262579 |
26 reports for REGN
85% Hit rate best @ T+60▲ +26.47%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 1d ago | ANALYST-UPGRADE | — | awaiting T+20 | — | — |
Sep 3, 2026 29d ago | Insider Cluster | $843.47 $735.20 | ▼ −12.84% | ▼ −11.65% | $735.20 (−12.84%) |
Aug 24, 2026 5w ago | Court Ruling | $828.50 $803.90 | ▼ −2.97% | ▼ −4.28% | $735.20 (−11.26%) |
Aug 20, 2026 6w ago | Press Release | $826.64 $784.85 | ▼ −5.06% | ▼ −5.06% | $735.20 (−11.06%) |
Aug 12, 2026 7w ago | Insider Cluster | $797.99 $793.26 | ▼ −0.59% | ▲ +1.30% | $735.20 (−7.87%) |
Aug 11, 2026 7w ago | Court Ruling | $797.00 $807.65 | ▲ +1.34% | ▲ +2.40% | $735.20 (−7.75%) |
Jul 30, 2026 9w ago | 8-K | $738.34 $807.71 | ▲ +9.40% | ▲ +5.43% | $735.20 (−0.43%) |
Jul 30, 2026 9w ago | Press Release | $738.34 $807.71 | ▲ +9.40% | ▲ +5.43% | $735.20 (−0.43%) |
Jul 27, 2026 9w ago | Press Release | $695.18 $833.56 | ▼ −19.91% | ▼ −16.52% | $735.20 (−5.76%) |
Jul 17, 2026 11w ago | Press Release | $676.69 $800.70 | ▲ +18.33% | ▲ +13.88% | $735.20 (+8.65%) |
Showing 10 of 26
US Market Status
Market Closed — Opens Mon (64h 12m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access